No. As of September 2026, SAB Biotherapeutics, Inc. (SABS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 76.9% / 30% · Interest income / Revenue 160800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 39.0% / 33% · Receivables / Mkt Cap (36m) 0.56% / 49% · Interest income / Revenue 160800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 39.0% / 33.33% · Receivables / Mkt Cap (24m) 0.56% / 33.33% · Interest income / Revenue 160800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.68% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 45.9% / 33.33% · Receivables / Avg Assets (4Q) 0.65% / 33.33% · Interest income / Revenue 160800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 44.2% / 33.33% · (Cash+Recv) / Total Assets 44.8% / 33.33% · Interest income / Revenue 160800000.0% / 5% | Fail |
No. As of September 2026, SAB Biotherapeutics, Inc. (SABS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. SAB Biotherapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 160800000.0% of each dividend: SAB Biotherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a Healthcare company (Biotechnology) with a market capitalization of $266M. The Maz Rating grades it against the other companies in its sector.
SAB Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.95, SAB Biotherapeutics, Inc. trades at 1.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -40.0%, return on invested capital of -38.4% and a free cash flow yield of -27.4%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 7.28. Over the past 52 weeks the share price ranged from $2.44 to $5.15, with a beta of 0.58.
SAB Biotherapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.